Table 2.

CBMN-cyt assay parameters and plasma 8-OHdG levels of patients with dyslipidemia before and after treatment with statins and of control subjects. Data are given as median (min–max).

	Control subjects (n = 20)	Before treatment with statins (n = 30)	After treatment with statins (n = 30)	P valuea	P valueb	P valuec
Frequency of MN (%)	0.75 (0.10–1.60)	1.70 (0.70–7.50)	0.75 (0.10–2.80)	<0.001	0.612	<0.001
Frequency of NPBs (%)	0.50 (0.10–1.30)	0.45 (0.00–3.10)	0.30 (0.00–1.00	0.329	<0.05	<0.05
Frequency of NBUDs (%)	0.25 (0.10–0.50)	0.20 (0.00–1.00)	0.20 (0.00–0.90)	0.919	0.410	0.147
Frequency of apoptotic cells (%)	0.80 (0.10–1.80)	1.05 (0.40–2.40)	0.90 (0.30–2.00)	<0.05	0.296	<0.001
Frequency of necrotic cells (%)	1.35 (0.10–1.90)	1.40 (0.20–2.60	1.00 (0.20–2.30)	0.538	0.180	<0.001
Frequency of BN cells (%)	29.90 (10.60–50.10)	41.80 (11.6–120.20)	28.45 (9.60–78.00)	<0.05	0.890	<0.01
NDI	1.26 (1.11–1.44)	1.35 (1.11–1.85)	1.24 (1.09–1.46)	<0.05	0.781	<0.01
Plasma 8-OHdG levels (ng/mL)	0.69 (0.44–1.02)	1.34 (0.33–1.99)	1.18 (0.56–2.25)	<0.01	<0.001	0.957

BN cells: binucleated cells; MN: micronucleus; NBUDs: nuclear buds; NDI: nuclear division index; NPBs: nucleoplasmic bridges; 8-OHdG: 8-hydroxy-2′-deoxyguanosine.

NDI  =  [M1 + 2(M2) + 3(M3) + 4(M4)]/N, where M1–M4 represents the total number of lymphocytes with one to four nuclei scored on 1000 viable cells (excluding necrotic and apoptotic cells; M: the number of nuclei; N: the total number of viable cells scored).

^ap value when the comparisons are between the control and before treatment with statin values (Mann–Whitney U test).

^bp value when the comparisons are between the control and after treatment with statin values (Mann–Whitney U test).

^cp value when the comparisons are between the before treatment and after treatment with statin values (Wilcoxon test).